Citigroup Inc Fulcrum Therapeutics, Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 178,564 shares of FULC stock, worth $1.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

178,564

Previous 285,298 37.41%

Holding current value

$1.1 Million

Previous $1.93 Million 12.47%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$6.7 - $12.0 $715,117 - $1.28 Million	-106,734 Reduced 37.41%	178,564 $1.69 Million
Q4 2023 Feb 09, 2024	BUY	$3.18 - $6.86 $623,626 - $1.35 Million	196,109 Added 219.88%	285,298 $1.93 Million
Q3 2023 Nov 09, 2023	BUY	$3.25 - $6.08 $264,179 - $494,218	81,286 Added 1028.55%	89,189 $395,000
Q2 2023 Aug 10, 2023	BUY	$2.26 - $3.8 $13,996 - $23,533	6,193 Added 362.16%	7,903 $26,000
Q1 2023 May 11, 2023	SELL	$2.83 - $13.99 $121 - $601	-43 Reduced 2.45%	1,710 $4,000

Q4 2022 Feb 09, 2023	SELL	$5.35 - $7.28 $893 - $1,215	-167 Reduced 8.7%	1,753 $12,000
Q3 2022 Nov 10, 2022	SELL	$4.92 - $9.1 $8,954 - $16,562	-1,820 Reduced 48.66%	1,920 $16,000
Q2 2022 Aug 10, 2022	SELL	$4.2 - $24.0 $107,049 - $611,712	-25,488 Reduced 87.2%	3,740 $18,000
Q1 2022 May 12, 2022	SELL	$9.96 - $23.65 $111,601 - $264,998	-11,205 Reduced 27.71%	29,228 $691,000
Q4 2021 Feb 10, 2022	BUY	$14.0 - $28.44 $463,652 - $941,875	33,118 Added 452.74%	40,433 $715,000
Q3 2021 Nov 10, 2021	BUY	$7.28 - $30.97 $53,253 - $226,545	7,315 New	7,315 $206,000

Others Institutions Holding FULC

# of Institutions

135

Shares Held

43.7M

Call Options Held

3.12M

Put Options Held

128K

View Full List

About Fulcrum Therapeutics, Inc.

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $321M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

More about FULC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account